Cinnamomum burmannii Bioactives as VEGFR-2 Inhibitors in Colon Cancer: A Chemoinformatics Approach
Year: 2026
Type: article
Abstract: Colon cancer is among the most prevalent cancers globally, with its progression closely associated with angiogenesis, primarily mediated by the activation of vascular endothelial growth factor receptor 2 (VEGFR-2). Although VEGFR-2 inhibitors such as apatinib have demonstrated efficacy in colon cancer therapy, their clinical use is limited due to potential side effects and high treatment costs. Natural compounds from Cinnamomum burmannii, which are known to contain secondary metabolites including flavonoids, saponins, phenols, tannins, and sterols/triterpenoids, present a potential alternative. This study aims to evaluate the inhibitory potential of C. burmannii bioactive compounds against VEGFR-2 using a computational-based approach. The methodology involved Lipinski's rule of five (RO5) analysis, ADMET (absorption, distribution, metabolism, excretion, and toxicity) prediction, pharmacophore screening, and molecular docking simulations. Among the screened compounds, methylhydroxychalcone emerged as the most promising candidate, exhibiting a favorable binding affinity with a Gibbs free energy of −8.51 kcal/mol and an inhibition constant of 579.80 nM. It also fulfilled drug-likeness criteria and displayed a good pharmacokinetic profile. Notably, methylhydroxychalcone interacted with the Asp1046 residue on VEGFR-2, a key interaction site also targeted by Apatinib. These findings support the potential of cinnamon bark-derived compounds, particularly methylhydroxychalcone, as prospective VEGFR-2 inhibitors for colon cancer therapy.
Source: Jurnal Riseta Naturafarm
DOI: 10.70392/jrn.v3i2.32
Institution: Padjadjaran University
Language: English
Subfield: Drug Discovery
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W7229506353
